Keystone Symposia

This meeting took place in 2016

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Fibrosis: From Basic Mechanisms to Targeted Therapies (Q3)

Organizer(s) Robert Lafyatis, Paolo G.V. Martini, Dean Sheppard and Lucie Peduto
February 7—11, 2016
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Oct 8, 2015
Abstract Deadline: Nov 10, 2015
Scholarship Deadline: Oct 8, 2015
Discounted Registration Deadline: Dec 8, 2015

Sponsored by Bayer HealthCare Pharmaceuticals, Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Shire Human Genetic Therapies and Theravance Biopharma

Summary of Meeting:
Fibrosis is the primary process of many diseases and the end-stage of many more, frequently leading to organ failure. However, the mechanisms leading to fibrosis have been poorly understood and available therapeutics targeting fibrosis limited. Increasingly, fibrosis is understood as a dynamic process that is orchestrated by the immune system, or activated by inflammation or cellular stress. Fibrosis of lung, kidney, skin, liver and muscle typically follow a variety of different stimuli. Advances in understanding Th2 cell responses, cell death, the inflammasome and ER and oxidative stresses provide new insights into such stimuli. Understanding the regulation of and interaction between profibrotic cytokines such as TGFb, IL-13, and CTGF are shedding additional light on fibrotic processes. Recent studies indicate that fibrosis is mediated by dedicated progenitor and resident cells within target tissues. Fibroblast and perivascular cell phenotype and differentiation are regulated not only by cytokines, but also by matrix composition and stiffness. Advances in the treatment of idiopathic pulmonary fibrosis and systemic sclerosis herald many new anti-fibrotic therapies that will soon enter clinical trials. Thus, mechanistic understandings will soon answer the long-standing clinical challenges of fibrotic and end-stage scarring diseases. This meeting aims to: 1) Present and discuss the most current and cutting-edge results regarding the mechanisms, signaling pathways, gene regulation, cells and tissues involved in fibrotic diseases and therapeutic approaches currently in development; 2) Include discussions and presentation of new ideas or paradigms that challenge existing models and expand on the knowledge of the current standard of care for fibrotic diseases; 3) Consider the future directions of the field, including the identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies developed and used in other related fields; 4) Stimulate collaborations in a setting conducive to focused, intense discussion among scientists with broad interests in fibrotic diseases and different targeted therapeutic approaches, including engagement with industrial partners interested in new targets in fibrotic disease; and 5) Provide a forum for trainees and new investigators to learn about current work in the field, to present their own work and to network with established investigators.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Richard Lee Gieseck III
NIAID, National Institutes of Health, USA

Bridget Hindman
National Institute of Occupational Safety and Health, USA

Patrice Mimche
University of Utah, USA

National Heart, Lung, and Blood Institute (NHLBI) Scholarship Recipients

Brendon M. Baker
Boston University, USA

Dwight M. Chambers
Georgia Institute of Technology / Emory University, USA

Houfu Guo
MD Anderson Cancer Center, USA

Andrew Haak
Mayo Clinic, USA

Ram P. Naikawadi
University of California, San Francisco, USA

Meredith L. Sosulski
Tulane University School of Medicine, USA

Victoria Stefanelli
Georgia Institute of Technology, USA